KF1 Stage II had the highest reported network instability signal.
Stage-associated cross-sectional network analysis.
- DNB genes
- 36
Source locator: Methods 2.2; Results 3.1; Fig. 1
Article · 2025 Deep GEO
Optimized Dynamic Network Biomarker Deciphers a High-Resolution Heterogeneity Within Thyroid Cancer Molecular Subtypes
Med Research
Official Abstract
The progression of differentiated thyroid carcinoma (DTC) poses significant clinical challenges, especially in determining the optimal time for intervention. To capture early signals of disease progression, we employed an optimized dynamic network biomarker (DNB) method—a systems biology approach that detects abrupt molecular changes indicating a critical transition signal. This analysis revealed that Stage II marks a critical transition in the disease trajectory. We further developed a scoring system called TCPSLevel (Thyroid Carcinoma Progression Signature Level), which quantifies individual progression risk based on gene expression profiles. TCPSLevel showed strong associations with clinical features and prognosis across multiple datasets. Our ensemble consensus clustering approach uncovered three robust DTC molecular subtypes, which demonstrated distinct clinical outcomes, immune microenvironments, regulatory landscapes, and therapeutic agents. A clinically applicable classifier (miniPC) was constructed using machine learning to facilitate subtype prediction. We also identified ASPH as a key regulator driving progression and validated its expression and function experimentally. Together, these findings offer new insights and practical tools for early risk assessment and personalized management of thyroid cancer.
Text reproduced verbatim from Version of Record (source); DOI; CC-BY-4.0.
Cite this paper
Plain citation
Haonan Zhang, Ge Zhang, Pengyuan Xu, Fengyi Yu, Liwen Li, Runzhi Huang, Pengpeng Zhang, Kaisaierjiang Kadier, Yuanyuan Wang, Qiqi Gu, Yalei Ding, Tianshu Gu, Hao Chi, Shiqian Zhang, Ruhao Wu, Yudi Xu, Shanshan Zhu, Honglin Zheng, Taiqi Zhao, Qi He, Xinguang Qiu. Optimized Dynamic Network Biomarker Deciphers a High-Resolution Heterogeneity Within Thyroid Cancer Molecular Subtypes. Med Research. 2025;1(1):10–31. https://doi.org/10.1002/mdr2.70004
Evidence Scale
Optimized Dynamic Network Biomarker Deciphers a High-Resolution Heterogeneity Within Thyroid Cancer Molecular Subtypes
Stage-associated DNB analysis, TCPSLevel, a compact subtype classifier and ASPH follow-up are presented as distinct evidence layers.
- GEO microarray cohorts
- 21 cohorts, plus TCGA
- TCGA count in Methods
- 544
- TCGA count in GRN analysis
- 484
- scRNA cells in Methods
- 17,709
- scRNA cells in Results
- 17,518
- Reported single-cell donors
- 1
- Human tissue specimens
- 48 tumor and 48 adjacent specimens
Counting note
TCGA counts of 544 in Methods and 484 in GRN analysis describe different reported analytical stages; no reason for excluding the numerical difference is inferred. Methods reports 17,709 cells and Results 17,518, without a reconstructed QC-exclusion process. One reported donor is not a large participant cohort; 48 tumor and 48 adjacent specimens do not mean 96 independent patients. Cohorts, cells, paired specimens and cultured-cell experiments are not added into a unique-participant total. External validation means retrospective expression-template/classifier evaluation, not prospective clinical utility.
Research Question
Can stage-associated transcriptional networks support thyroid-cancer subtyping and nominate experimentally assessable progression-related candidates?
Author Evidence Summary
The study connects stage-associated computational analysis with subtype classification and experimental candidate assessment. A stage-ordered network signal is not direct observation of an individual patient's future transition. Human tissue associations, cell perturbation and computational therapeutic hypotheses are presented separately.
Key Findings
KF2 TCPSLevel was associated with clinical and outcome differences.
Expression-score construction and retrospective association.
| Measure | Value |
|---|---|
| Expression bins | 100 |
| Background samplings | 1,000 |
| Reported survival cutoff | 0.4 |
Source locator: Methods 2.4; Results 3.2; Fig. 2
KF3 The ensemble analysis yielded three molecular subtypes.
Consensus framework selection and external NTP evaluation.
| Measure | Value |
|---|---|
| Candidate combinations | 20 |
| Selected combination | CV-PAM |
| Reported external NTP datasets | 6 |
Source locator: Methods 2.6-2.7; Results 3.3; Fig. 3
KF4 miniPC classified the consensus subtype labels using a compact gene set.
Gene selection and external subtype-classifier evaluation.
| Measure | Value |
|---|---|
| Candidate genes | 296 |
| Final genes | 12 |
| Final classifier | Neural network |
| External classifier cohorts | 5 |
Source locator: Methods 2.8; Results 3.4; Fig. 4
KF5 Single-cell analysis localized expression patterns across cellular compartments.
Single-donor single-cell analysis with separately reported Methods and Results counts.
| Measure | Value |
|---|---|
| Reported donors | 1 |
| Cells in Methods | 17,709 |
| Cells in Results | 17,518 |
| Annotated populations | 7 |
Source locator: Methods 2.1.1 and 2.3; Results 3.7; Fig. 5K-N
KF6 ASPH was evaluated in human tissues and through TPC-1 silencing.
Human tissue association and separate cultured-cell perturbation.
| Measure | Value |
|---|---|
| Tumor specimens | 48 |
| Adjacent specimens | 48 |
| TPC-1 silencing | Reduced proliferation and migration |
Source locator: Methods: tissue and cell experiments; Results 3.6 and 3.8; Fig. 6
KF7 IPS and CMap supplied candidate immune/drug-response hypotheses.
Computational treatment-related hypothesis generation.
- Evidence
- Computational scoring and signature matching
Source locator: Methods 2.10 and 2.20; Results 3.5 and 3.9; Figure 7G-I; Discussion
Study Design & Analytical Framework
Study profile
- Study Design
- Public bulk/single-cell analysis with human tissue assessment and cell experiments
- Evidence Type
- Retrospective molecular subtyping with experimental candidate follow-up
- Population
- Thyroid-cancer datasets and tissue specimens, with separate cultured-cell experiments
- Primary Endpoint
- DNB-associated expression structure and molecular subtype assignment
- Secondary Endpoint
- Retrospective outcome associations and ASPH-related experimental readouts
- External dataset evaluation
- Yes
Data modalities
- bulk transcriptomics
- single-cell RNA sequencing
- network/classifier analysis
- human immunohistochemistry
- in-vitro gene perturbation
What This Study Adds
- Connects stage-associated network analysis with molecular subtyping.
- Distinguishes subtype discovery from subtype-classifier evaluation.
- Separates human tissue, cultured-cell and computational drug-hypothesis evidence.
Evidence Scope
Supports
- Stage II had the highest reported network instability signal.
- TCPSLevel was associated with clinical and outcome differences.
- The ensemble analysis yielded three molecular subtypes.
- miniPC classified the consensus subtype labels using a compact gene set.
- Single-cell analysis localized expression patterns across cellular compartments.
- ASPH was evaluated in human tissues and through TPC-1 silencing.
- IPS and CMap supplied candidate immune/drug-response hypotheses.
Does Not Establish
- Longitudinal prediction of an individual patient's transition time.
- Clinical intervention benefit.
- miniPC as an established survival model rather than a subtype classifier.
- Cell counts as patient counts or paired-specimen counts as independent participants.
- Complete demonstration of direct ASCL2 regulation or binding.
- Clinical efficacy of CMap-nominated compounds.
- Classification of this study as a physiological circadian-rhythm experiment.
- Resolution of all Methods/Results counts or accession differences.
Limitations
- TCGA counts of 544 in Methods and 484 in GRN analysis describe different reported analytical stages; no reason for excluding the numerical difference is inferred. Methods reports 17,709 cells and Results 17,518, without a reconstructed QC-exclusion process. One reported donor is not a large participant cohort; 48 tumor and 48 adjacent specimens do not mean 96 independent patients. Cohorts, cells, paired specimens and cultured-cell experiments are not added into a unique-participant total. External validation means retrospective expression-template/classifier evaluation, not prospective clinical utility.
- Cross-sectional stage comparisons do not establish longitudinal prediction of each patient's future deterioration time.
- The reported cutoff is not a cross-cohort locked clinical threshold. Grouping rules used in other analyses are not automatically equivalent.
- Methods 2.6 prints GSE333630 whereas other locations use GSE33630. These are not silently rewritten as a fully verified accession inventory.
- This is subtype classification, not prospective individual survival-benefit validation. Unverified figure-only accuracy or AUC values are not reconstructed.
- A single donor and a large cell count do not establish large-population replication. No explanation for the count difference is invented.
- Paired tissues are not 96 independent patients. ASCL2-ASPH network inference is not direct binding validation, and cell effects do not establish human targeted-treatment efficacy.
- Predicted compounds are not proven effective treatments. IPS is not an observed outcome in patients receiving immunotherapy.
- Longitudinal prediction of an individual patient's transition time.
- Clinical intervention benefit.
- miniPC as an established survival model rather than a subtype classifier.
- Cell counts as patient counts or paired-specimen counts as independent participants.
- Complete demonstration of direct ASCL2 regulation or binding.
- Clinical efficacy of CMap-nominated compounds.
- Classification of this study as a physiological circadian-rhythm experiment.
- Resolution of all Methods/Results counts or accession differences.
When This Study Is Useful to Cite
- CU1: Which thyroid studies applied dynamic network biomarkers to stage-associated expression?
Stage II had the highest reported network instability signal. DNB genes: 36. Cross-sectional stage comparisons do not establish longitudinal prediction of each patient's future deterioration time. TCPSLevel was associated with clinical and outcome differences. Expression bins: 100; Background samplings: 1,000; Reported survival cutoff: 0.4. The reported cutoff is not a cross-cohort locked clinical threshold. Grouping rules used in other analyses are not automatically equivalent.
- CU2: What evidence supports ensemble thyroid-cancer molecular subtyping?
The ensemble analysis yielded three molecular subtypes. Candidate combinations: 20; Selected combination: CV-PAM; Reported external NTP datasets: 6. Methods 2.6 prints GSE333630 whereas other locations use GSE33630. These are not silently rewritten as a fully verified accession inventory.
Evidence: KF3
- CU3: How was a compact classifier developed for consensus thyroid subtypes?
miniPC classified the consensus subtype labels using a compact gene set. Candidate genes: 296; Final genes: 12; Final classifier: Neural network; External classifier cohorts: 5. This is subtype classification, not prospective individual survival-benefit validation. Unverified figure-only accuracy or AUC values are not reconstructed.
Evidence: KF4
- CU4: What evidence distinguishes ASPH expression association from experimental perturbation?
Single-cell analysis localized expression patterns across cellular compartments. Reported donors: 1; Cells in Methods: 17,709; Cells in Results: 17,518; Annotated populations: 7. A single donor and a large cell count do not establish large-population replication. No explanation for the count difference is invented. ASPH was evaluated in human tissues and through TPC-1 silencing. Tumor specimens: 48; Adjacent specimens: 48; TPC-1 silencing: Reduced proliferation and migration. Paired tissues are not 96 independent patients. ASCL2-ASPH network inference is not direct binding validation, and cell effects do not establish human targeted-treatment efficacy.
- CU5: What computational rather than clinical therapeutic hypotheses were generated?
IPS and CMap supplied candidate immune/drug-response hypotheses. Evidence: Computational scoring and signature matching. Predicted compounds are not proven effective treatments. IPS is not an observed outcome in patients receiving immunotherapy.
Evidence: KF7
What This Study Should Not Be Cited to Claim
- Longitudinal prediction of an individual patient's transition time.
- Clinical intervention benefit.
- miniPC as an established survival model rather than a subtype classifier.
- Cell counts as patient counts or paired-specimen counts as independent participants.
- Complete demonstration of direct ASCL2 regulation or binding.
- Clinical efficacy of CMap-nominated compounds.
- Classification of this study as a physiological circadian-rhythm experiment.
- Resolution of all Methods/Results counts or accession differences.
Evidence Matrix
| Row ID | Component | Context | Finding | Evidence Level | Scope | Source Locator | Evidence refs |
|---|---|---|---|---|---|---|---|
| evidence-thyroid-1 | Stage-associated DNB inference | Stage-associated cross-sectional network analysis. | Stage II had the highest reported network instability signal. DNB genes: 36 | Retrospective expression and computational evidence | Cross-sectional stage comparisons do not establish longitudinal prediction of each patient's future deterioration time. | Methods 2.2; Results 3.1; Fig. 1 | KF1 |
| evidence-thyroid-2 | TCPSLevel construction and association | Expression-score construction and retrospective association. | TCPSLevel was associated with clinical and outcome differences. Expression bins: 100; Background samplings: 1,000; Reported survival cutoff: 0.4 | Retrospective expression and computational evidence | The reported cutoff is not a cross-cohort locked clinical threshold. Grouping rules used in other analyses are not automatically equivalent. | Methods 2.4; Results 3.2; Fig. 2 | KF2 |
| evidence-thyroid-3 | Consensus subtype framework | Consensus framework selection and external NTP evaluation. | The ensemble analysis yielded three molecular subtypes. Candidate combinations: 20; Selected combination: CV-PAM; Reported external NTP datasets: 6 | Retrospective expression and computational evidence | Methods 2.6 prints GSE333630 whereas other locations use GSE33630. These are not silently rewritten as a fully verified accession inventory. | Methods 2.6-2.7; Results 3.3; Fig. 3 | KF3 |
| evidence-thyroid-4 | miniPC subtype classifier | Gene selection and external subtype-classifier evaluation. | miniPC classified the consensus subtype labels using a compact gene set. Candidate genes: 296; Final genes: 12; Final classifier: Neural network; External classifier cohorts: 5 | Retrospective expression and computational evidence | This is subtype classification, not prospective individual survival-benefit validation. Unverified figure-only accuracy or AUC values are not reconstructed. | Methods 2.8; Results 3.4; Fig. 4 | KF4 |
| evidence-thyroid-5 | Single-cell context | Single-donor single-cell analysis with separately reported Methods and Results counts. | Single-cell analysis localized expression patterns across cellular compartments. Reported donors: 1; Cells in Methods: 17,709; Cells in Results: 17,518; Annotated populations: 7 | Retrospective expression and computational evidence | A single donor and a large cell count do not establish large-population replication. No explanation for the count difference is invented. | Methods 2.1.1 and 2.3; Results 3.7; Fig. 5K-N | KF5 |
| evidence-thyroid-6 | ASPH experimental follow-up | Human tissue association and separate cultured-cell perturbation. | ASPH was evaluated in human tissues and through TPC-1 silencing. Tumor specimens: 48; Adjacent specimens: 48; TPC-1 silencing: Reduced proliferation and migration | Human tissue association and in-vitro perturbation | Paired tissues are not 96 independent patients. ASCL2-ASPH network inference is not direct binding validation, and cell effects do not establish human targeted-treatment efficacy. | Methods: tissue and cell experiments; Results 3.6 and 3.8; Fig. 6 | KF6 |
| evidence-thyroid-7 | Computational therapeutic hypotheses | Computational treatment-related hypothesis generation. | IPS and CMap supplied candidate immune/drug-response hypotheses. Evidence: Computational scoring and signature matching | Retrospective expression and computational evidence | Predicted compounds are not proven effective treatments. IPS is not an observed outcome in patients receiving immunotherapy. | Methods 2.10 and 2.20; Results 3.5 and 3.9; Figure 7G-I; Discussion | KF7 |
Q&A
What does the Stage II DNB signal establish?
Stage II had the highest reported network instability signal. DNB genes: 36. Cross-sectional stage comparisons do not establish longitudinal prediction of each patient's future deterioration time.
Evidence: KF1
Is TCPSLevel already a clinically validated prospective risk tool?
TCPSLevel was associated with clinical and outcome differences. Expression bins: 100; Background samplings: 1,000; Reported survival cutoff: 0.4. The reported cutoff is not a cross-cohort locked clinical threshold. Grouping rules used in other analyses are not automatically equivalent.
Evidence: KF2
How were the thyroid molecular subtypes evaluated externally?
The ensemble analysis yielded three molecular subtypes. Candidate combinations: 20; Selected combination: CV-PAM; Reported external NTP datasets: 6. Methods 2.6 prints GSE333630 whereas other locations use GSE33630. These are not silently rewritten as a fully verified accession inventory.
Evidence: KF3
Does miniPC classify subtypes or directly prove improved survival?
miniPC classified the consensus subtype labels using a compact gene set. Candidate genes: 296; Final genes: 12; Final classifier: Neural network; External classifier cohorts: 5. This is subtype classification, not prospective individual survival-benefit validation. Unverified figure-only accuracy or AUC values are not reconstructed.
Evidence: KF4
How many independent donors support the single-cell analysis?
Single-cell analysis localized expression patterns across cellular compartments. Reported donors: 1; Cells in Methods: 17,709; Cells in Results: 17,518; Annotated populations: 7. A single donor and a large cell count do not establish large-population replication. No explanation for the count difference is invented.
Evidence: KF5
What human and experimental evidence supports ASPH?
ASPH was evaluated in human tissues and through TPC-1 silencing. Tumor specimens: 48; Adjacent specimens: 48; TPC-1 silencing: Reduced proliferation and migration. Paired tissues are not 96 independent patients. ASCL2-ASPH network inference is not direct binding validation, and cell effects do not establish human targeted-treatment efficacy.
Evidence: KF6
Were CMap-nominated compounds shown to benefit patients?
IPS and CMap supplied candidate immune/drug-response hypotheses. Evidence: Computational scoring and signature matching. Predicted compounds are not proven effective treatments. IPS is not an observed outcome in patients receiving immunotherapy.
Evidence: KF7
Concepts & Entities
Disease
Entities
Methods
Evidence
Related Research
Publication & Provenance
- DOI
- https://doi.org/10.1002/mdr2.70004
- Doi Url
- https://doi.org/10.1002/mdr2.70004
- Publisher
- https://onlinelibrary.wiley.com/doi/full/10.1002/mdr2.70004
- Review Basis
- Evidence synthesis from the cited main text, figure legends and designated primary records. No independent reanalysis of participant-level data. Unavailable supplementary or figure-only details are not reconstructed.
Author-controlled evidence synthesis, distinct from the published abstract and not a replacement for the version of record. Source-specific counting and interpretation limits are retained.
Study-level evidence table
Study-level author-maintained evidence summary. Not participant-level data and not a ready-to-pool meta-analysis dataset. For formal citation, use the original article DOI.
Download study-level evidence CSV (UTF-8)Formula safety: cells starting with =, +, -, @ (after leading whitespace), or tab/CR/LF are prefixed with an apostrophe. Treat all cells as text; remove only that safety prefix when recovering the original string.
Verify publication identity
These records identify the same original work; database inclusion is not evidence of scientific validity or clinical benefit.